Self-Assessment Exam

1. The number of new cases of choroidal neovascularization (CNV) occurring each year in the United States is:   
   
   A. 200,000   
   B. 300,000   
   C. 400,000   
   D. 500,000
   
   
2. Which of the following statement is false regarding photocoagulation and photodynamic therapy (PDT)?   
   
   A. Both therapies use lasers at low light levels.   
   B. Correct interpretation of the fluorescein angiogram is critical to evaluate whether lesions would benefit from these procedures.   
   C. Large-scale randomized trials have demonstrated a reduction of risk of vision loss from CNV in patients with age-related macular degeneration.   
   D. All of the above statements are false.
   
   
3. Lesion size is determined by:   
   A. Measuring the greatest linear dimension then adding 500 µm.   
   B. Landmarks, i.e., retinal vessels, areas of blood, pigment or lipid.   
   C. Both A and B are correct.   
   D. None of the above.
   
   
4. In photocoagulation, the wavelength used in the treatments is:   
   A. Green.   
   B. Yellow.   
   C. Red.   
   D. All of the above.
   
   
5. Photodynamic therapy (PDT) is a two-step process that involves:   
   A. The activation of a photosensitizer with a thermal laser.   
   B. The activation of a photosensitizer with a nonthermal laser.   
   C. Both A and B can be used in PDT.   
   D. Neither A nor B can be used in PDT.
   
   
6. The Macular Photocoagulation Study (MPS) group reported that subfoveal photocoagulation should be considered beneficial in eyes with:   
   A. Relatively good visual acuity.   
   B. Large neovascular lesions.   
   C. Small, well-defined neovascular lesions.   
   D. All of the above.
   
   
7. The laser wavelength that matches the absorption peak of the photosensitizer used in PDT is:   
   A. Green.   
   B. Yellow,   
   C. Red.   
   D. All of the above.
   
   
8. The Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) study group reported __________ percentage of patients with predominantly CNV lesions who were treated with verteporfin experienced less than three lines of vision loss after one year follow-up.   
   A. 26 percent.   
   B. 39 percent.   
   C. 53 percent.   
   D. 67 percent.
   
   
9. Laser specifications for PDT include:   
   A. Retinal spot size of 500-6400 µm.   
   B. Fluence (light dose) of 50 J/cm2.   
   C. Irradiance of 600 mW/cm2.   
   D. All of the above.
   
   
10. Treatment parameters of the Visulas 690s that must be set (i.e., are not preset) prior to treatment include:   
    A. Light dose and spot size.   
    B. Exposure time and power density.   
    C. Exposure time and dye timer.   
    D. Contact lens magnification and spot size.